Year None2024202320222021202020192018201720162015 Nov 15 Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) Nov 13 Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH Nov 11 Regeneron Announces Investor Conference Presentations Nov 6 Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Oct 31 Regeneron Reports Third Quarter 2024 Financial and Operating Results Oct 24 Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI Oct 18 Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema Sep 27 Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD Sep 27 Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) Sep 26 Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page »